Precision Cancer Consortium的动态

We believe that nonprofit organizations have a vital role to play in fixing the broken generic drug marketplace in the US. At NP2, we are committed to producing a steady supply of injectable oncology drugs at affordable prices. #Nonprofitpharma #Generics #Oncology

Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing ? Propanc Biopharma, Inc. (OTCQB:PPCB), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, shares his views on revolutionizing cancer treatment with an inside look at drug development and strategic financing. Mr. Nathanielsz appeared on a show with Mr. Joel Block, a weekly podcast on killer business strategies and how the best leaders make them work. In this week’s episode, Mr. Nathanielsz discusses the competitive advantage of the Company and its enzyme treatment for metastatic cancer. ? https://lnkd.in/gGY3pvmJ ? #propanc #ppcb #biopharma #cancer #oncology?

SEPTEMBER: Ovarian Cancer Awareness Month!?? As we mark Ovarian Cancer Awareness Month, let's unite to shine a light on this often-silent killer. Ovarian cancer affects thousands of women worldwide, often diagnosed at a late stage due to unclear symptoms and lack of early detection tests. Let's change this! Join me in supporting research, awareness, and advocacy efforts. Together, we can: - Support those affected by ovarian cancer and their loved ones - Educate ourselves, our families, and communities about ovarian cancer, its symptoms, complications, stages, types, and drugs. -Here are the few drugs in this post for ovarian cancer: 1. AbbVie's Elahere 2. GSK's Zejula 3. pharma&'s Rubraca 4. AstraZeneca's Lynparza 5. Genentech's (Member of Roche) Avastin 6. Eli Lilly and Company's Gemzar #ovariancancer?#ovariancancerawarenessmonth #tealribbons #ovariancancerresearch #supportthecause #makeadifference #ovariancancersurvivor #shine #womenshealth?#cancerfighter #elahere #zejula #rubraca #lynparza #Avastin #gemzar Reach out to Octavus Consulting for more posts about the current pharmaceutical market and healthcare updates

?? Promising strides in clinical research: ISLA-101, manufactured by Island Pharmaceuticals moves forward to Phase 2b! Know complete story: https://lnkd.in/gyzMNdH6 ?? Dr. Reddy's Laboratories brings innovation to the US with Ivermectin tablets launch! Know complete story: https://lnkd.in/gjp57WSR ?? Shuttle Pharmaceuticals, Inc. progresses with Ropidoxuridine trial for breakthrough cancer care! Know complete story: https://lnkd.in/gyXnxU7a ?? Big win for oncology in Japan: Delta-Fly Pharma株式会社 receives approval from Japanese Lung Cancer Society! Know complete story: https://lnkd.in/g6vmHrS7 #PharmaNews #ClinicalTrials #HealthcareInnovation #DrugLaunch #PharmaceuticalIndustry #Oncology #GlobalHealth #MedicalResearch

We are excited to announce that Oncology News Today will be joining us as the official media partner for the upcoming 8th DDR Inhibitors Summit. This event is the premier gathering for biopharma drug developers and researchers, offering a unique platform to collaborate and drive advancements in DDR therapeutics. Learn more here: https://ter.li/tzqidv." ? Oncology News Today is a trusted and accessible resource for oncology healthcare professionals, delivering timely news and updates that support oncology care across the UK. ? Since its launch in Summer 2022, the platform has grown into a comprehensive ‘one-stop shop’ for all things oncology, collaborating with leading organizations in the field. ? Oncology News Today shares the latest news, jobs, events and On Air podcast episodes across its social media platforms and through its free monthly newsletter. ? Click here to find out more: https://lnkd.in/e4w7jd7d ? #OncologyNewsToday #DDRInhibitorsSummit #OncologyCare #Oncology #DDRInhibitors

Join us at #BIO2024 for a compelling session that delves into the heart of biopharma deals: "Is Oncology Still a Hot Spot for Biopharma Deals?" ?? Date: Thursday, June 6, 2024 ?? Time: 10:15 – 11:15 a.m. Oncology has long been the frontrunner in biopharma investments, with a staggering 37% of the clinical-stage drug pipeline dedicated to cancer treatments. But when it comes to M&A, the landscape is shifting. What does this mean for the industry? Our session will analyze industry data to compare oncology vs. non-oncology companies in the context of M&A and Alliances and gain our experts' opinions on where things are headed. Ben Hickey,?Ross Aarons, Camille Landis,?Christopher Mortko

?? Partnering for lives: Carebot & Bristol Myers Squibb join forces to combat lung cancer ?? At Carebot, we believe in the power of AI to change lives. Today, we're proud to announce a powerful new partnership with Bristol Myers Squibb, focused on one of the toughest battles in healthcare—early detection of lung cancer. ?? Lung cancer often hides until it's too late, taking away precious time from patients and their families. Together with Bristol Myers Squibb, the world's leading biopharmaceutical company, we’re changing that. By integrating our AI-powered solution into hospitals, we aim to help doctors identify even the smallest signs of cancer sooner, giving patients a fighting chance when it matters most. ?? This collaboration isn’t just about technology—it’s about hope. It’s about getting care to those who need it most, and giving patients the opportunity for earlier, more effective treatment. We’re excited to take this step towards a future where no lesion is left behind, and every patient has a better chance at recovery.?

Pro Bono in the Spotlight: The Anticancer Fund ?? Highlighting our assistance to the Anticancer Fund, a global research and non-profit organization dedicated to finding new treatments for cancer. ?????? ????????: Crowell’s Kristof Roox and Wietse Vanpoucke advise the Anticancer Fund on the EU pharmaceutical package, a regulation aimed at making the pharmaceutical system patient-centered and ensuring that patients benefit from equitable access to safe and affordable therapies. ?????? ???? ??????????????: The Anticancer Fund repurposes non-cancer drugs for oncology, to address the urgent need for effective and accessible cancer treatments. ?? “Working with the Anticancer Fund has been an incredibly rewarding experience. It’s inspiring to contribute to a cause that is making such a significant difference in the fight against cancer.” — Wietse Vanpoucke At Crowell, we believe in using our legal expertise and human resources to make a positive impact. Public service and supporting pro bono initiatives align with our commitment to giving back to our community. For more information about the Anticancer Fund ?? https://lnkd.in/gPTKMGe #ProBono #AnticancerFund #MakingADifference

Looking back at the 2024 edition of the American Society of Clinical Oncology (ASCO) Annual Meeting which just came to an end, we, at Pfizer, feel more hopeful and enthusiastic than ever. The richness of innovations and results presented were exceptional, including some of our own recent data which we could share with this international audience of renowned experts. We are proud that Pfizer is leading the change on this matter with significant investments in its Oncology organization (Pfizer now directs around 40% its R&D investment into developing new oncology therapies), uniting industry-leading expertise, an expanded portfolio, and the global reach to deliver treatments rapidly. Our scientists are at the cutting edge, developing next-generation therapies across small molecules, antibody-drug conjugates (ADCs), and immuno-oncology biologics. Our vision is steadfast: a world where cancer patients live better, longer lives. We're not merely developing treatments; we're fostering hope and improving life quality for those affected by cancer. #PfizerBelgium #Oncology #CancerResearch #ASCO

?? Unveiling Insights: ESR1 Mutated Metastatic Breast Cancer Market ?? DelveInsight Business Research LLP's latest report on the ESR1 Mutated #MetastaticBreastCancerMarket dives deep into the evolving landscape of this complex condition. The leading Esr1-mutated #MetastaticBreastCancerCompanies such as AstraZeneca, Olema Oncology Pharmaceuticals, Arvinas, Sermonix Pharmaceuticals, Roche, Eli Lilly and Company, H3 Biomedicine, Eisai Co., Ltd., Pfizer, Sun Pharma Advanced Research Company Ltd. ZENOPHARM LLC, and others. ?? Download the report now to explore the breakthroughs shaping the future of ESR1 mutated metastatic breast cancer treatment @ https://lnkd.in/dfgrQz-p #DelveInsight #BreastCancerMarket #ESR1Mutations #MetastaticBreastCancer #HealthcareInsights #MarketResearch #PharmaIndustry #Oncology